Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 12, 2005, Pages 1467-1474

  Castell, D ^a   Bagin, R ^b   Goldlust, B ^b   Major, J ^b   Hepburn, B ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Santarus Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED DRUG RELEASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; NIGHT; OPEN STUDY; PATIENT MONITORING; PH MEASUREMENT; PHARMACODYNAMICS; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; SUSPENSION; TABLET;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; POWDERS; SULFOXIDES; TREATMENT OUTCOME;

EID: 21044452799     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02513.x     Document Type: Article

References (22)

1. Dent J, Hetzel DJ, MacKinnon MA, Reed WD, Narielvala FM. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol 1989; 24 (Suppl. 166): 76-82.
2. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa. Eur J Gastroenterol Hepatol 1996; 8: 1101-6.
3. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
4. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
5. Goldlust B, Hepburn B, Hardiman Y. Nighttime dosing of omeprazole immediate-release oral suspension rapidly decreases nocturnal gastric acidity. Am J Gastroenterol 2004; 99: S39 (Abstract 116).
6. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.
7. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545-50.
8. Modlin IM, Sachs G, eds. Acid-related Diseases - Biology and Treatment. Milan, Italy: Schnetzor-Verlag GmbH D-Konstanz, 1998.
9. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267-72.
10. Tutuian R, Castell D. Nocturnal acid breakthrough - approach to management. Med Gen Med 2004; 6: 11.
11. Hammer J, Schmidt K. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004; 19: 1105-10.
12. Peghini PL, Katz PO, Castell DO. Rantidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
13. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
14. Horrocks JC, De Dombal FT. Clinical presentation of patients with 'dyspepsia': detailed symptomatic study of 360 patients. Gut 1978; 19: 19-26.
15. Shaker R, Castell D, Schoenfeld P, Spechler S. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487-93.
16. Food and Drug Administration Website. Label for Prevacid®. Available at: http://www.fda.gov/cder/foi/label/2004/ 020406s057_021281s014_021428s004lbl%20.pdf, accessed on 8 March 2005.
17. Food and Drug Administration Website. Label for Prilosec®. Available at: http://www.fda.gov/cder/foi/label/2004/19810se8-058.slr003_prilosec_lbl.pdf, accessed on 8 March 2005.
18. Food and Drug Administration Website. Label for Protonix®. Available at: http://www.fda.gov/cder/foi/label/2004/20987slr020_protonix_lbl.pdf, accessed on 8 March 2005.
19. Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve GERD symptoms for patients on proton pump inhibitor therapy. Proceedings of the 69th ACG Annual Meeting, 2004: October 29-November 30, Orlando, Florida, USA, 2004: 110.
20. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001; 15: 487-95.
21. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4.
22. Conrad S, Gabrielli A, Margolis B, et al. A randomized double-blind comparison of immediate-release omeprazole oral suspension vs. intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33: 760-5.